我们提出了一种荟萃分析方法，通过综合生存模型来量化 NSCLC 疾病负担。来自公共来源的汇总生存数据被用来参数化早期和晚期 NSCLC 阶段的模型，包括化疗、靶向治疗和免疫治疗。根据不同的分层和初始条件，在异质患者队列中预测总生存期 (OS)。对药物经济学指标（获得的生命年 (LYG) 和获得的质量调整生命年 (QALY)）进行评估，以量化专门治疗的益处和改善 NSCLC 的早期检测。模拟显示，针对晚期 NSCLC 亚组引入新疗法将中位生存期延长了 8.1 个月（95% CI：5.9，10.0），LYG 和 1.65 的中位生存期相应增加了 2.9 个月（95% CI：2.2，3.6）。 QALY 个月（95% CI：1.2，2.0）。整个患者队列中早期癌症检测得到改善的场景显示，中位生存期分别增加了 17.6 个月（95% CI：16.5、19.0）和 15.7 个月（95% CI：14.8、16.6），分别增加了 6.2 个月（ LYG 的 95% CI：5.9，6.4）和 5.2 个月（95% CI：4.9，5.4）；常规 QALY 的 6.6 个月（95% CI：6.4，6.7）和 6.0 个月（95% CI：5.9，6.2）和最佳治疗。这个综合建模平台旨在描述癌症负担的特征，可以精确量化在治疗方案中引入专门疗法的累积效益以及早期发现疾病时延长生存期。© 2024 作者。

We present a meta-analytics approach to quantify NSCLC disease burden by integrative survival models. Aggregated survival data from public sources were used to parameterize the models for early as well as advanced NSCLC stages incorporating chemotherapies, targeted therapies, and immunotherapies. Overall survival (OS) was predicted in a heterogeneous patient cohort based on various stratifications and initial conditions. Pharmacoeconomic metrics (life years gained (LYG) and quality-adjusted life years (QALY) gained), were evaluated to quantify the benefits of specialized treatments and improved early detection of NSCLC. Simulations showed that the introduction of novel therapies for the advanced NSCLC sub-group increased median survival by 8.1 months (95 % CI: 5.9, 10.0), with corresponding gains of 2.9 months (95 % CI: 2.2, 3.6) in LYG and 1.65 months (95 % CI: 1.2, 2.0) in QALY. Scenarios representing improved detection of early cancer in the whole patient cohort, revealed up to 17.6 (95 % CI: 16.5, 19.0) and 15.7 months (95 % CI: 14.8, 16.6) increase in median survival, with respective gains of 6.2 months (95 % CI: 5.9, 6.4) and 5.2 months (95 % CI: 4.9, 5.4) in LYG and 6.6 months (95 % CI: 6.4, 6.7) and 6.0 months (95 % CI: 5.9, 6.2) in QALY for conventional and optimal treatment. This integrative modeling platform, aimed at characterizing cancer burden, allows to precisely quantify the cumulative benefits of introducing specialized therapies into the treatment schemes and survival prolongation upon early detection of the disease.© 2024 The Authors.